Scientists seek better way to collect poop for microbiome studies
NCT ID NCT07452965
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find the best way to collect and handle stool samples for gut bacteria (microbiota) research. Researchers will compare different collection methods to the standard quick-freeze technique. Ten healthy adults aged 18 to 85 will provide samples. The goal is to improve accuracy in future microbiome studies, not to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male and/or female * Age between 18 and 85 years * No diagnosed pathology * Not opposed to following the study procedures Exclusion Criteria: * Ongoing digestive neoplasia or \< 5 years * Digestive surgery with intestinal resection * Presence of inflammatory bowel disease or other familial gastrointestinal pathology * Chronic use of laxatives * Use of antibiotics in the two months prior to inclusion * Life-threatening conditions in the short term (progressive cancer, unstable heart failure, severe liver, kidney or respiratory failure) * Chronic psychosis or psychotic episodes * Alcohol or drug addiction * Epilepsy and other non-degenerative diseases of the central nervous system * Vitamin B12 and folic acid deficiency not supplemented * Untreated hypothyroidism * Pregnant or breastfeeding woman * Person deprived of liberty by judicial or administrative decision * Major protected by law * Not affiliated with a social security scheme or beneficiary of such a scheme * Having a period of relative exclusion in relation to another protocol * Having refused to participate in the protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Montpellier
Montpellier, France, 34295, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others
- Tiny doses, big questions: how does the body handle this prodrug?
- First human test of CM583: can this biologic pass the safety check?